643
Participants
Start Date
November 7, 2012
Primary Completion Date
January 7, 2015
Study Completion Date
January 7, 2015
Denosumab
Denosumab 60 mg administered by subcutaneous injection once every 6 months.
Zoledronic Acid
Zoledronic acid 5 mg administered by intravenous infusion once a year
Placebo to Denosumab
Administered by subcutaneous injection once every 6 months
Placebo to Zoledronic Acid
Administered by intravenous infusion once a year
Research Site, Brussels
Research Site, Brussels
Research Site, Brussels
Research Site, Brussels
Research Site, Maroubra
Research Site, St Leonards
Research Site, Merksem
Research Site, Wilrijk
Research Site, Penrith
Research Site, Ballerup Municipality
Research Site, Leuven
Research Site, Parkville
Research Site, Box Hill
Research Site, Geelong
Research Site, Genk
Research Site, Tessenderlo
Research Site, Liège
Research Site, Yvoir
Research Site, Vejle
Research Site, Aalborg
Research Site, West Haverstraw
Research Site, Granada
Research Site, Washington D.C.
Research Site, Bethesda
Research Site, Hagerstown
Research Site, Madrid
Research Site, Madrid
Research Site, Detroit
Research Site, Houston
Research Site, Lakewood
Research Site, Longmont
Research Site, Santa Monica
Research Site, Calgary
Research Site, Vancouver
Research Site, Halifax
Research Site, Toronto
Research Site, Toronto
Research Site, Toronto
Research Site, Québec
Research Site, Bialystok
Research Site, Krakow
Research Site, Torun
Research Site, Warsaw
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
Amgen
INDUSTRY